Please login to the form below

Not currently logged in
Email:
Password:

Former FDA adviser joins Precision for Medicine

Vicki Seyfert-Margolis appointed chief of science and strategy at life science research company

Precision for Medicine Vicki Seyfert-Margolis Precision for Medicine has appointed former US FDA senior adviser Dr Vicki Seyfert-Margolis to the role of chief of science and strategy.

Dr Seyfert-Margolis served as senior adviser, regulatory science and innovation at the US regulator, reporting directly to the commissioner.

During this time, she led the FDA's regulatory science and personalised medicine initiative, as well as strategies for promoting innovation in drug development.

Prior to her time with the FDA, Dr Seyfert-Margolis was chief science officer at the Immune Tolerance Network, a global research initiative to discover biomarkers for autoimmune disorders.

In her new role at Precision for Medicine, which provides research support to life science companies, Dr Syfert-Margolis will guide the company's scientific strategy and provide insight and support for its clients.

“Precision for Medicine shares my vision for the future of healthcare - one where the patient is not just the end user, but the focal point of all aspects of drug, diagnostic, and device development,” said Dr Seyfert-Margolis.

19th April 2013

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics